Open AccessLangerhans Cell Histiocytosis in Adults: Treatment Opportunities of Today
Author(s) -
Vitalii Dmitrievich Latyshev,
Elena Lukina
Publication year - 2021
Publication title -
kliničeskaâ onkogematologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.116
H-Index - 2
eISSN - 2500-2139
pISSN - 1997-6933
DOI - 10.21320/2500-2139-2021-14-4-444-454
Subject(s) - langerhans cell histiocytosis , histiocytosis , pathological , infiltration (hvac) , pathogenesis , medicine , clinical practice , disease , rare disease , pathology , physical therapy , physics , thermodynamics
Langerhans cell histiocytosis (LCH) is an extremely rare disease associated with tissue infiltration by pathological cells which are phenotypically similar to normal Langerhans cells. Standard therapy of LCH in adults has not been developed so far, due to the lack of sufficient evidence base for different treatment methods. In clinical practice, cytostatic treatment is applied along with new approaches using signaling pathway inhibitors involved in LCH pathogenesis. This literature review covers currently existing methods of LCH therapy in adults and their feasibility in clinical practice.